The predicted increase in PAK2 inhibitor sensitivity in presence of WT TP53 was confirmed by enhanced responses to PAK‐5339 observed in the 5 HPV(−) HNSCC models with WT TP53 in GDSC data (Fig. 3C). Here, PAK2 is linked to head and neck squamous cell carcinoma.